[go: up one dir, main page]

DE602005005843D1 - 4 ä(2,4-dichloro-5-methoxyphenyl)aminoü-6-alkoxy-7-ethynyl-3-quinolinecarbonitrile zur behandlung von ischämie - Google Patents

4 ä(2,4-dichloro-5-methoxyphenyl)aminoü-6-alkoxy-7-ethynyl-3-quinolinecarbonitrile zur behandlung von ischämie

Info

Publication number
DE602005005843D1
DE602005005843D1 DE602005005843T DE602005005843T DE602005005843D1 DE 602005005843 D1 DE602005005843 D1 DE 602005005843D1 DE 602005005843 T DE602005005843 T DE 602005005843T DE 602005005843 T DE602005005843 T DE 602005005843T DE 602005005843 D1 DE602005005843 D1 DE 602005005843D1
Authority
DE
Germany
Prior art keywords
aminoü
quinolinecarbonitrile
ethynyl
ischemia
methoxyphenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602005005843T
Other languages
English (en)
Other versions
DE602005005843T2 (de
Inventor
Diane Harris Boschelli
Margaret Zaleska
Ana Carolina Barrios-Sosa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth LLC filed Critical Wyeth LLC
Publication of DE602005005843D1 publication Critical patent/DE602005005843D1/de
Application granted granted Critical
Publication of DE602005005843T2 publication Critical patent/DE602005005843T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38Nitrogen atoms
    • C07D215/42Nitrogen atoms attached in position 4
    • C07D215/44Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/47064-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE602005005843T 2004-10-22 2005-10-21 4 ä(2,4-dichloro-5-methoxyphenyl)aminoü-6-alkoxy-7-ethynyl-3-chinolincarbonitrile zur behandlung von ischämie Expired - Lifetime DE602005005843T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62128004P 2004-10-22 2004-10-22
US621280P 2004-10-22
PCT/US2005/037839 WO2006047262A1 (en) 2004-10-22 2005-10-21 4 [(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-7-ethynyl-3-quinolinecarbonitriles for the treatment of ischemic injury

Publications (2)

Publication Number Publication Date
DE602005005843D1 true DE602005005843D1 (de) 2008-05-15
DE602005005843T2 DE602005005843T2 (de) 2009-05-14

Family

ID=35784691

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005005843T Expired - Lifetime DE602005005843T2 (de) 2004-10-22 2005-10-21 4 ä(2,4-dichloro-5-methoxyphenyl)aminoü-6-alkoxy-7-ethynyl-3-chinolincarbonitrile zur behandlung von ischämie

Country Status (23)

Country Link
US (1) US20060116375A1 (de)
EP (1) EP1802581B1 (de)
JP (1) JP2008517924A (de)
KR (1) KR20070085413A (de)
CN (1) CN101044117A (de)
AT (1) ATE391122T1 (de)
AU (1) AU2005299822A1 (de)
BR (1) BRPI0516995A (de)
CA (1) CA2581807A1 (de)
CR (1) CR9072A (de)
DE (1) DE602005005843T2 (de)
DK (1) DK1802581T3 (de)
EC (1) ECSP077385A (de)
ES (1) ES2303287T3 (de)
IL (1) IL182547A0 (de)
MX (1) MX2007004833A (de)
NO (1) NO20071708L (de)
PL (1) PL1802581T3 (de)
PT (1) PT1802581E (de)
RU (1) RU2007111704A (de)
SI (1) SI1802581T1 (de)
WO (1) WO2006047262A1 (de)
ZA (1) ZA200703275B (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200829555A (en) * 2006-11-10 2008-07-16 Astrazeneca Ab Chemical compounds
CN102952037A (zh) * 2012-11-18 2013-03-06 大连九信生物化工科技有限公司 一种2-氰基-n-(2,4-二氯-5-甲氧苯基)乙酰胺的合成方法
WO2014086284A1 (zh) * 2012-12-04 2014-06-12 上海医药集团股份有限公司 一类氘代3-氰基喹啉类化合物、其药用组合物、制备方法及其用途
CN114436851B (zh) * 2022-01-17 2023-08-22 常州大学 一种n,n-二甲基苄胺及其衍生物的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6297258B1 (en) * 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
US6521618B2 (en) * 2000-03-28 2003-02-18 Wyeth 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
TWI275390B (en) * 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
US20040229880A1 (en) * 2003-02-21 2004-11-18 Wyeth 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-3-quinolinecarbonitriles for the treatment of ischemic injury

Also Published As

Publication number Publication date
SI1802581T1 (sl) 2008-08-31
ATE391122T1 (de) 2008-04-15
MX2007004833A (es) 2007-05-16
PL1802581T3 (pl) 2008-09-30
DK1802581T3 (da) 2008-06-30
ECSP077385A (es) 2007-05-30
PT1802581E (pt) 2008-06-03
WO2006047262A1 (en) 2006-05-04
DE602005005843T2 (de) 2009-05-14
AU2005299822A1 (en) 2006-05-04
CR9072A (es) 2007-09-07
ZA200703275B (en) 2008-08-27
EP1802581B1 (de) 2008-04-02
JP2008517924A (ja) 2008-05-29
IL182547A0 (en) 2007-09-20
EP1802581A1 (de) 2007-07-04
CN101044117A (zh) 2007-09-26
BRPI0516995A (pt) 2008-09-30
ES2303287T3 (es) 2008-08-01
NO20071708L (no) 2007-07-13
RU2007111704A (ru) 2008-11-27
HK1104555A1 (en) 2008-01-18
KR20070085413A (ko) 2007-08-27
US20060116375A1 (en) 2006-06-01
CA2581807A1 (en) 2006-05-04

Similar Documents

Publication Publication Date Title
RU2495044C2 (ru) Ингибиторы активности протеинтирозинкиназы
EA201001669A1 (ru) Замещенные пиримидин-5-карбоксамиды 281
ECSP066760A (es) Derivado de 4-oxopirimidina de anillos condensados
EA200970461A1 (ru) ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 3-ИЗОБУТИЛ-9,10-ДИМЕТОКСИ-1,3,4,6,7,11b-ГЕКСАГИДРО-2Н-ПИРИДО[2,1-a]ИЗОХИНОЛИН-2-ОЛА И СВЯЗАННЫЕ С НИМИ СПОСОБЫ
EA200870577A1 (ru) Конденсированные трициклические сульфонамидные ингибиторы гамма-секретазы
EA200700099A1 (ru) Производные пиридина
EA200200716A1 (ru) Арилконденсированные азаполициклические соединения
JO2282B1 (en) Oxazole derivatives
EA200802329A1 (ru) Производные триазола ii
GB0005357D0 (en) Compounds
EA200300333A1 (ru) Новые тиадиазолы и оксадиазолы и их применение в качестве ингибиторов фосфодиэстеразы-7
ATE389395T1 (de) Substituierte 2-aminotetraline zur vorbeugenden behandlung von morbus parkinson
DE60206911D1 (de) Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren
EA200802173A1 (ru) Производные терфенила для лечения болезни альцгеймера
EA200970793A1 (ru) Модуляторы рецепторов, активируемых пролифераторами пероксисом
EA201270266A1 (ru) Гетероциклические соединения
RU2011112684A (ru) АГЕНТ, СПОСОБСТВУЮЩИЙ РОСТУ ВОЛОС, СОДЕРЖАЩИЙ В КАЧЕСТВЕ АКТИВНОГО ИНГРЕДИЕНТА ПРОИЗВОДНОЕ 15,15-ДИФТОРПРОСТАГЛАНДИНА F2α
MXPA05008706A (es) 4-[(2, 4- dicloro-5 -metoxifenil) amino]-6 -alcoxi -3- quinolincarbonitrilos para tratamiento de lesiones isquemicas.
DE602007011434D1 (de) 1h-indol-5-ylpiperazin-1-ylmethanonderivate
TW200716547A (en) Piperidin-4-yl-amide derivatives
MY139704A (en) Naphthalene derivatives for use as histamine-3-receptor ligands
TW200727893A (en) Methods for treating sexual dysfunction
EA200701780A1 (ru) Противоопухолевое средство
EA200701035A1 (ru) Замещенные n-сульфониламинобензил-2-феноксиацетамидные соединения
ZA200703275B (en) 4 [(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-7-ethynyl-3-quinollnecarbonitriles for the treatment of ischemic Injury

Legal Events

Date Code Title Description
8364 No opposition during term of opposition